BioTuesdays

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

Model Medicines Logo

Closely held Model Medicines has announced the unveiling of a generative AI-driven, multi-modal therapeutic pipeline breakthrough, showcasing its end-to-end drug discovery capabilities for novel target discovery, mechanism of action (MoA) insights, and preclinical proof-of-concept (PoC) success.

In the company’s latest pre-print, titled “GALILEO™ Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next-Generation Broad-Spectrum Antiviral Compounds at High Hit Rates.” , the generative AI, New Chemical Entity (NCE), multi-modal modeling, one-shot identification, and library-scale hit-rate capabilities of its proprietary GALILEO platform are highlighted.

According to Model Medicines, this pre-print, along with three previously released pre-prints, underscores the company’s comprehensive drug discovery capabilities, spanning novel target and MoA discovery, novel chemical discovery, and preclinical PoC validation against a first-in-class Target Product Profile (TPP) at unprecedented hit-rates of 100% leveraging generative AI, multi-modal models and a 0/1-shot discovery approach.

In a statement, Dr. Daniel Haders, CEO of Model Medicines and corresponding author, remarked, “This research exemplifies the promise of AI-driven, end-to-end drug discovery. From target identification through to the creation of novel chemical entities to proof-of-concept validation, GALILEO integrates biology, chemistry, and computational power to engineer entirely new therapeutic opportunities with unprecedented speed and precision.”